3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
115
Squamous Cell Carcinoma of Head and Neck
61
Triple Negative Breast Neoplasms
57
Melanoma
54
Neoplasm Metastasis
49
Lung Neoplasms
49
Breast Neoplasms
41
Neoplasms
36
Colorectal Neoplasms
35
Head and Neck Neoplasms
25
Endometrial Neoplasms
25
Carcinoma, Renal Cell
24
Uterine Cervical Neoplasms
21
Stomach Neoplasms
21
Ovarian Neoplasms
21
Carcinoma, Transitional Cell
21
Urinary Bladder Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Esophageal Neoplasms
16
Recurrence
15
Carcinoma, Hepatocellular
14
Pancreatic Neoplasms
13
Sarcoma
12
Carcinoma, Squamous Cell
12
Glioblastoma
11
Esophageal Squamous Cell Carcinoma
11
Carcinoma
11
Prostatic Neoplasms
10
Brain Neoplasms
10
Carcinoma, Merkel Cell
9
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
pembrolizumab
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled